A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine whether, in patients with moderate to severe
plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis
symptoms and the extent to which the patient's body area is affected by the disease (compared
to placebo).